OBJECTIVE: To examine whether the activation of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in serotonin production, is associated with depressive symptoms. METHODS: The participants were 544 women and 442 men (aged 24-39 years) from the population-based Young Finns Study who participated in a medical examination in 2001 (including IDO and depression) and 2007 (follow-up assessment for depression). RESULTS: At baseline, IDO was associated with depressive symptoms (in the total cohort: B = 0.23, p < .001; women: B = 0.20, p = .007; men: B = 0.29, p = .002; p for interaction = .19). IDO at baseline was also associated with depressive symptoms at follow-up in women (B = 0.17, p = .03), which remained significant when adjusting for any of the biologic and behavioral risk factors. Adjusting for body mass index attenuated the association by 6%. In the final model including all baseline variables, none of the risk factors (except for baseline depressive symptoms) were associated with depressive symptoms at follow-up. CONCLUSIONS: These data suggest that IDO activity may be a risk factor for future depression especially in women. IDO-induced alterations in serotonergic function may offer one biologic explanation to the well-established associations between inflammation and depression.
OBJECTIVE: To examine whether the activation of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in serotonin production, is associated with depressive symptoms. METHODS: The participants were 544 women and 442 men (aged 24-39 years) from the population-based Young Finns Study who participated in a medical examination in 2001 (including IDO and depression) and 2007 (follow-up assessment for depression). RESULTS: At baseline, IDO was associated with depressive symptoms (in the total cohort: B = 0.23, p < .001; women: B = 0.20, p = .007; men: B = 0.29, p = .002; p for interaction = .19). IDO at baseline was also associated with depressive symptoms at follow-up in women (B = 0.17, p = .03), which remained significant when adjusting for any of the biologic and behavioral risk factors. Adjusting for body mass index attenuated the association by 6%. In the final model including all baseline variables, none of the risk factors (except for baseline depressive symptoms) were associated with depressive symptoms at follow-up. CONCLUSIONS: These data suggest that IDO activity may be a risk factor for future depression especially in women. IDO-induced alterations in serotonergic function may offer one biologic explanation to the well-established associations between inflammation and depression.
Authors: Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo Journal: J Psychiatr Res Date: 2015-05-19 Impact factor: 4.791
Authors: Lauren M F Merlo; Elizabeth Pigott; James B DuHadaway; Samantha Grabler; Richard Metz; George C Prendergast; Laura Mandik-Nayak Journal: J Immunol Date: 2014-01-31 Impact factor: 5.422
Authors: Lauren M F Merlo; Samantha Grabler; James B DuHadaway; Elizabeth Pigott; Kaylend Manley; George C Prendergast; Lisa D Laury-Kleintop; Laura Mandik-Nayak Journal: Clin Immunol Date: 2017-02-20 Impact factor: 3.969
Authors: Sarah M Clark; Ana Pocivavsek; James D Nicholson; Francesca M Notarangelo; Patricia Langenberg; Robert P McMahon; Joel E Kleinman; Thomas M Hyde; John Stiller; Teodor T Postolache; Robert Schwarcz; Leonardo H Tonelli Journal: J Psychiatry Neurosci Date: 2016-10 Impact factor: 6.186